Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kewaunee Scientific (KEQU) Capital Expenditures (2016 - 2026)

Kewaunee Scientific (KEQU) has 16 years of Capital Expenditures data on record, last reported at $1.6 million in Q4 2025.

  • For Q4 2025, Capital Expenditures rose 129.87% year-over-year to $1.6 million; the TTM value through Oct 2025 reached $3.5 million, up 46.83%, while the annual FY2025 figure was $2.2 million, 50.47% down from the prior year.
  • Capital Expenditures reached $1.6 million in Q4 2025 per KEQU's latest filing, up from $771000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $2.6 million in Q2 2023 and bottomed at $278000.0 in Q3 2024.
  • Average Capital Expenditures over 5 years is $802050.0, with a median of $647500.0 recorded in 2021.
  • Peak YoY movement for Capital Expenditures: surged 324.1% in 2023, then crashed 83.19% in 2024.
  • A 5-year view of Capital Expenditures shows it stood at $446000.0 in 2021, then rose by 18.61% to $529000.0 in 2022, then soared by 139.13% to $1.3 million in 2023, then plummeted by 46.01% to $683000.0 in 2024, then soared by 129.87% to $1.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Capital Expenditures were $1.6 million in Q4 2025, $771000.0 in Q3 2025, and $516000.0 in Q2 2025.